Clinical Trials
6
Active:1
Completed:5
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Oncozyme Pharma Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02210182
- Locations
- 🇨🇦
Dr. Kelly Burak, Calgary, Alberta, Canada
🇨🇦Dr Morris Sherman, Toronto, Ontario, Canada
🇨🇦Dr Marc Bilodeau, Montreal, Quebec, Canada
An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Oncozyme Pharma Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01844791
- Locations
- 🇵🇱
Ewa Kalinka-Warzocha, Lodz, Poland
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Drug: OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Oncozyme Pharma Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT01378143
- Locations
- 🇨🇦
CSSS Champlain - Charles-Lemoyne Hospital, Greenfield Park, Quebec, Canada
🇨🇦CSSS Alphonse-Desjardins (CHAU Hotel-Dieu de Levis), Levis, Quebec, Canada
🇨🇦CHUM-St. Luc Hospital, Montreal, Quebec, Canada
A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Oncozyme Pharma Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00810953
- Locations
- 🇨🇦
McGill University, Montreal, Quebec, Canada
A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Oncozyme Pharma Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00809796
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
News
No news found